Second-line therapy of squamous non-small cell lung cancer: an evolving landscape-Reference-Cited by-同舟云学术

Second-line therapy of squamous non-small cell lung cancer: an evolving landscape

Published:2017-05-15 Issue:6 Volume:11 Page:469-479
ISSN:1747-6348
Container-title:Expert Review of Respiratory Medicine
language:en
Short-container-title:Expert Review of Respiratory Medicine

Author:

Lazzari Chiara¹,Karachaliou Niki²,Gregorc Vanesa¹,Bulotta Alessandra¹,Gonzalez-Cao Maria³,Verlicchi Alberto⁴,Altavilla Giuseppe⁵,Rosell Rafael³⁶⁷,Santarpia Mariacarmela⁵

Affiliation:

1. Department of Oncology, Division of Experimental Medicine, IRCCS San Raffaele, Milan, Italy

2. Medical Oncology Department, Institute of Oncology Rosell (IOR), University Hospital Sagrat Cor, Barcelona, Spain

3. Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Dexeus University Hospital-Quirónsalud Group, Barcelona, Spain

4. S.C. Oncologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

5. Medical Oncology Unit, Department of Human Pathology “G. Barresi”, University of Messina, Messina, Italy

6. Germans Trias i Pujol Research Institute, Badalona, Spain

7. Catalan Institute of Oncology, Germans Trias i Pujol University Hospital, Badalona, Spain

Publisher

Informa UK Limited

Subject

Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/17476348.2017.1326822

Reference90 articles.

1. Global Cancer Incidence and Mortality Rates and Trends—An Update

2. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

3. Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive

4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

5. Targeting ALK in patients with advanced Non Small Cell Lung Cancer: Biology, diagnostic and therapeutic options

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of oxidative stress signatures of lung adenocarcinoma and prediction of patient prognosis or treatment response with single-cell RNA sequencing and bulk RNA sequencing data;International Immunopharmacology;2024-08

2. Development and validation of a combined glycolysis and immune prognostic signature for lung squamous cell carcinoma;Frontiers in Genetics;2022-09-30

3. Identification of an Innate Immune-Related Prognostic Signature in Early-Stage Lung Squamous Cell Carcinoma;International Journal of General Medicine;2021-11

4. Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges;Chinese Medical Journal;2021-08-02

5. Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma;Journal for ImmunoTherapy of Cancer;2020-10